Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Metastatic Colorectal Cancer”

252 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 252 results

Testing effectiveness (Phase 2)Ended earlyNCT01060423
What this trial is testing

TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer
Hans-Joachim Schmoll, MD 8
Early research (Phase 1)Ended earlyNCT02110953
What this trial is testing

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

Who this might be right for
Liver MetastasesMucinous Adenocarcinoma of the ColonMucinous Adenocarcinoma of the Rectum+8 more
Fox Chase Cancer Center 2
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Not applicableStudy completedNCT01996969
What this trial is testing

Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Seoul National University Hospital 117
Testing effectiveness (Phase 2)UnknownNCT05278351
What this trial is testing

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Who this might be right for
Colorectal Neoplasms Malignant
Shanghai Zhongshan Hospital 87
Early research (Phase 1)Study completedNCT00003439
What this trial is testing

Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

Who this might be right for
Cancer
National Cancer Institute (NCI) 36
Not applicableStudy completedNCT01486251
What this trial is testing

Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer

Who this might be right for
Colorectal Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris 27
Testing effectiveness (Phase 2)UnknownNCT05143099
What this trial is testing

Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC

Who this might be right for
Colorectal Neoplasms
Shanghai Zhongshan Hospital 35
Testing effectiveness (Phase 2)Study completedNCT02118064
What this trial is testing

Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma

Who this might be right for
Colorectal Cancer
Cancer Advances Inc. 161
Testing effectiveness (Phase 2)Study completedNCT01111838
What this trial is testing

Clinical and Translational Study of STA-9090

Who this might be right for
Colon CancerRectal Cancer
Memorial Sloan Kettering Cancer Center 20
Early research (Phase 1)Study completedNCT02743637
What this trial is testing

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

Who this might be right for
Advanced MalignancyAdvanced Solid TumorsNeoplasm+1 more
SynDevRx, Inc. 32
Testing effectiveness (Phase 2)UnknownNCT00081536
What this trial is testing

Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies

Who this might be right for
Colorectal Neoplasms
Aronex Pharmaceuticals 105
Not applicableStudy completedNCT05942768
What this trial is testing

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Adenocarcinoma
Hunan Cancer Hospital 103
Early research (Phase 1)Study completedNCT01154335
What this trial is testing

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
SCRI Development Innovations, LLC 18
Testing effectiveness (Phase 2)Study completedNCT01409005
What this trial is testing

Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer

Who this might be right for
Metastatic or Recurrent Colorectal CancerRefractory to Fluoropyrimidine, Oxaliplatin and IrinotecanSalvage Chemotherapy
Seoul National University Bundang Hospital 41
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT05205330
What this trial is testing

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Who this might be right for
Refractory Metastatic Colorectal CancerSolid TumorMetastatic Microsatellite-stable Colorectal Cancer+3 more
Rottapharm Biotech 107
Testing effectiveness (Phase 2)Study completedNCT00313794
What this trial is testing

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

Who this might be right for
Colorectal Neoplasms
AstraZeneca 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT04616183
What this trial is testing

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Adenocarcinoma+28 more
M.D. Anderson Cancer Center 46
Testing effectiveness (Phase 2)Study completedNCT00077259
What this trial is testing

Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Load More Results